ALK
ALK inhibitors are compounds that specifically target and inhibit Anaplastic Lymphoma Kinase (ALK), a receptor tyrosine kinase involved in the development and progression of certain cancers, including non-small cell lung cancer and neuroblastoma. By inhibiting ALK, these compounds block signaling pathways that promote tumor cell growth and survival. At CymitQuimica, we offer ALK inhibitors to support your research in oncology, targeted cancer therapies, and signal transduction.
Found 126 products of "ALK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
TP0427736 hydrochloride
CAS:TP0427736 hydrochloride is a novel and selective ALK5 inhibitor, capable of inhibiting Smad2/3 phosphorylation in A549 cells.Formula:C14H11ClN4S2Purity:98.99%Color and Shape:SolidMolecular weight:334.85MY10
CAS:MY10, a potent and orally active inhibitor of the receptor protein tyrosine phosphatase (RPTPβ/ζ), effectively reduces binge-like ethanol consumption andFormula:C15H10F6OS2Purity:98.64%Color and Shape:SolidMolecular weight:384.36Conteltinib
CAS:Conteltinib (CT-707) is an enzyme inhibitor with antitumor activity targeting FAK, ALK and Pyk2. It can be used to study lymphoma.Formula:C32H45N9O3SPurity:98.12% - 99.54%Color and Shape:SolidMolecular weight:635.82GW-6604
CAS:GW-6604 is an ALK5 inhibitor and shows clear antifibrotic effects resulting in liver function improvement.Formula:C19H14N4Purity:99.6%Color and Shape:SolidMolecular weight:298.34ALK/EGFR-IN-3
CAS:ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12ALK/EGFR-IN-1
CAS:ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.Formula:C27H34ClN7O3SPurity:98%Color and Shape:SolidMolecular weight:572.12ALK-IN-6
CAS:ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).Formula:C26H29ClD3N5O3SPurity:98%Color and Shape:SolidMolecular weight:533.1UNC5293
CAS:UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.Formula:C30H42N6O2Color and Shape:SolidMolecular weight:518.69ALK/ROS1-IN-1
CAS:ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).Formula:C30H35F3N6O3Purity:98%Color and Shape:SolidMolecular weight:584.63KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Formula:C26H30FN7OPurity:98.49% - >99.99%Color and Shape:SolidMolecular weight:475.56ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Formula:C23H22ClFN6OPurity:99.71%Color and Shape:SolidMolecular weight:452.91IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Formula:C25H20N6OPurity:99.79%Color and Shape:SolidMolecular weight:420.47CEP-14083
CAS:<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Formula:C31H30N6O2Color and Shape:SolidMolecular weight:518.61TGF-βRI inhibitor 3
CAS:<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Formula:C21H21NO4Color and Shape:SolidMolecular weight:351.396WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Formula:C33H45BrN8O5SColor and Shape:SolidMolecular weight:745.73ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Formula:C36H45N5O3Color and Shape:SolidMolecular weight:595.77DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColor and Shape:SolidMolecular weight:400.362PF-06463922 acetate
CAS:PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Formula:C23H23FN6O4Color and Shape:SolidMolecular weight:466.46ALK-IN-23
ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.Formula:C26H29ClN8O3SColor and Shape:SolidMolecular weight:569.08CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Formula:C32H30N6O3Color and Shape:SolidMolecular weight:546.619ALKBH5-IN-3
CAS:ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Formula:C11H7F3N2O3Purity:98.32%Color and Shape:SolidMolecular weight:272.18W23-1006
CAS:W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Formula:C17H12BrN3O5Color and Shape:SolidMolecular weight:418.198DA-0157
CAS:<p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>Formula:C31H43BrN7O2PColor and Shape:SolidMolecular weight:656.597AZ12601011
CAS:AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.Formula:C19H15N5Purity:98.81%Color and Shape:SolidMolecular weight:313.36Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formula:C21H20F3N5O3Purity:98.7%Color and Shape:SolidMolecular weight:447.41
